Glenmark gets ANDA approval for hypertension tablet

Agencies
Posted: Friday, Jul 10, 2009 at 1450 hrs IST
Updated: Friday, Jul 10, 2009 at 1450 hrs IST

Font Size

Feedback

Discuss

GSK Pharma Q3 profit rises 7%Dr Reddy's Q2 net up 3 fold at Rs 240 cr Piramal Healthcare Q2 net up 45 pct Ranbaxy hails US court ruling on Valcyte patent

Mumbai: Drug maker Glenmark Pharmaceuticals said its US based subsidiary, has got the Abbreviated New Drug Application (ANDA) approval from the US food and drug administration for Fosinopril Sodium and Hydrochlorothiazide tablet, used for the treatment of hypertension.

Glenmark Generics Inc, a subsidiary of the company has received ANDA approval through a partnership with another US based company, Invagen Pharmaceuticals Inc, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange.

"We are very pleased with this approval as it gives us the chance to provide customers with guaranteed and uninterrupted supply which they may not have been getting in the past. We anticipate a successful launch considering the limited competitive landscape coupled with the niche positioning of this product." Glenmark Generics Ltd Chief Executive Officer Terrance Coughlin said.

Fosinopril Sodium and Hydrochlorothiazide(HCTZ) tablets are available in both 10mg/12.5mg and 20mg/12.5mg strengths and are indicated for the treatment of hypertension, the filing said.

The company would exclusively market and distribute the product while InvaGen would be responsible for their manufacture and supply. All development, regulatory costs and profits on Fosinopril Sodium and Hydrochlorothiazide tablets' sale in the US would be shared equally between Glenmark and Invagen, it added.

Post Comments

Comments: (Limit 3,000 characters)

Name		Message
Email ID
Subject

TERMS OF USE:
The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).

I agree to the terms of use.